周三,诺瓦瓦克斯医药盘前直线跳水,一度暴跌近30%,消息称美国食品药品监督管理局(FDA)暂时搁置公司新冠流感疫苗临床试验申请。
对此,诺瓦瓦克斯医药表示,临床暂停是因为单个CIC 2期试验参与者发生了严重的运动神经病变事件的自发报告。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.